Insider Stock Trading History of Aviezer David


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Aviezer David since year 2005. The trader's CIK number is 1385112. At the time of this reporting, Aviezer David is the President & CEO of Protalix Biotherapeutics, Inc. . (stock ticker symbol PLX). See this page for all insider trading activities at Protalix Biotherapeutics, Inc. .


Stock purchases, sales, and option exercises reported by insider Aviezer David since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2012-05-02 PLX Protalix Biotherapeutics, Inc. Option Ex 450,000 .55 245,700
2012-05-02 PLX Protalix Biotherapeutics, Inc. Sale 450,000 7.13 3,208,500
2009-10-21 PLX Protalix Biotherapeutics, Inc. Option Ex 247,490 .12 29,698
2009-10-19 PLX Protalix Biotherapeutics, Inc. Sale 150,000 9.43 1,414,500
2009-10-20 PLX Protalix Biotherapeutics, Inc. Sale 60,000 9.45 567,000
2009-10-21 PLX Protalix Biotherapeutics, Inc. Sale 34,238 9.36 320,467
2009-05-08 PLX Protalix Biotherapeutics, Inc. Sale 5,200 3.40 17,680
2009-05-12 PLX Protalix Biotherapeutics, Inc. Option Ex 103,571 .12 12,428
2009-05-11 PLX Protalix Biotherapeutics, Inc. Sale 38,900 3.41 132,649
2009-05-12 PLX Protalix Biotherapeutics, Inc. Sale 55,900 3.41 190,619
2009-05-05 PLX Protalix Biotherapeutics, Inc. Sale 21,600 3.07 66,312
2009-05-06 PLX Protalix Biotherapeutics, Inc. Sale 20,000 3.01 60,199
2009-05-04 PLX Protalix Biotherapeutics, Inc. Sale 33,400 3.01 100,534
2009-05-06 PLX Protalix Biotherapeutics, Inc. Option Ex 78,061 .12 9,367
2009-04-16 PLX Protalix Biotherapeutics, Inc. Sale 6,700 2.50 16,750
2009-04-17 PLX Protalix Biotherapeutics, Inc. Sale 10,000 2.56 25,600
2009-04-20 PLX Protalix Biotherapeutics, Inc. Option Ex 52,469 .12 6,296
2009-04-20 PLX Protalix Biotherapeutics, Inc. Sale 33,300 2.51 83,583

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Aviezer David (President & CEO of Protalix Biotherapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.